Building new cardiac vasculature and myocardium: where are we
at?

J 2021

Building new cardiac vasculature and myocardium: where are we at?

SEDLÁKOVÁ, Veronika, M. AHUMADA, E. J. SUURONEN a E. I. ALARCON

Základní údaje

Originální název

Building new cardiac vasculature and myocardium: where are we at?

Autoři

SEDLÁKOVÁ, Veronika (203 Česká republika, domácí), M. AHUMADA, E. J. SUURONEN a E. I. ALARCON (garant)

Vydání

Current opinion in cardiology, Philadelpha, PA, Rapid Science Publishers, 2021, 0268-4705

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.108

Kód RIV

RIV/00216224:14110/21:00123962

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/HCO.0000000000000905

UT WoS

000703608800009

Klíčová slova anglicky

3D bioprinting; biomaterials; cardiac tissue; cell therapy; tissue engineering

Štítky

14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 2. 2022 10:35, Mgr. Tereza Miškechová

Anotace

V originále

Purpose of review This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. Recent findings Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.

Citovat

SEDLÁKOVÁ, Veronika, M. AHUMADA, E. J. SUURONEN a E. I. ALARCON. Building new cardiac vasculature and myocardium: where are we at? Current opinion in cardiology. Philadelpha, PA: Rapid Science Publishers, 2021, roč. 36, č. 6, s. 728-734. ISSN 0268-4705. Dostupné z: https://dx.doi.org/10.1097/HCO.0000000000000905.

@article{1827353,
   author = {Sedláková, Veronika and Ahumada, M. and Suuronen, E. J. and Alarcon, E. I.},
   article_location = {Philadelpha, PA},
   article_number = {6},
   doi = {http://dx.doi.org/10.1097/HCO.0000000000000905},
   keywords = {3D bioprinting; biomaterials; cardiac tissue; cell therapy; tissue engineering},
   language = {eng},
   issn = {0268-4705},
   journal = {Current opinion in cardiology},
   title = {Building new cardiac vasculature and myocardium: where are we at?},
   url = {https://journals.lww.com/co-cardiology/Abstract/2021/11000/Building_new_cardiac_vasculature_and_myocardium_.9.aspx},
   volume = {36},
   year = {2021}
}

TY  - JOUR
ID  - 1827353
AU  - Sedláková, Veronika - Ahumada, M. - Suuronen, E. J. - Alarcon, E. I.
PY  - 2021
TI  - Building new cardiac vasculature and myocardium: where are we at?
JF  - Current opinion in cardiology
VL  - 36
IS  - 6
SP  - 728-734
EP  - 728-734
PB  - Rapid Science Publishers
SN  - 02684705
KW  - 3D bioprinting
KW  - biomaterials
KW  - cardiac tissue
KW  - cell therapy
KW  - tissue engineering
UR  - https://journals.lww.com/co-cardiology/Abstract/2021/11000/Building_new_cardiac_vasculature_and_myocardium_.9.aspx
N2  - Purpose of review This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. Recent findings Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.
ER  -

SEDLÁKOVÁ, Veronika, M. AHUMADA, E. J. SUURONEN a E. I. ALARCON. Building new cardiac vasculature and myocardium: where are we at? \textit{Current opinion in cardiology}. Philadelpha, PA: Rapid Science Publishers, 2021, roč.~36, č.~6, s.~728-734. ISSN~0268-4705. Dostupné z: https://dx.doi.org/10.1097/HCO.0000000000000905.

Podrobný výpis o publikaci